Grail Inc
NASDAQ:GRAL
Grail Inc
Grail Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Menlo Park, California and currently employs 1,370 full-time employees. The company went IPO on 2024-06-12. GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. The company is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.
Grail Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Menlo Park, California and currently employs 1,370 full-time employees. The company went IPO on 2024-06-12. GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. The company is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.
Strong Growth: Galleri test volumes grew 39% and revenue rose 29% year-over-year in Q3, showing continued market uptake.
Financial Improvement: Net loss improved by 29% versus last year, and cash burn guidance for 2025 was reduced further to no more than $290 million.
Robust Cash Position: GRAIL ended Q3 with $547.1 million in cash and investments, expected to reach about $850 million after financing, not including a pending $110 million Samsung investment.
Clinical Milestones: New PATHFINDER 2 results showed Galleri's positive predictive value at 61.6% and specificity at 99.6%; updated SIMPLIFY data raised PPV in symptomatic patients to 84.2%.
FDA Timeline Update: The PMA submission timeline was accelerated and is now targeted for Q1 2026 instead of the first half of 2026.
International Expansion: GRAIL announced a collaboration with Samsung to commercialize Galleri in key Asian markets and launched in Canada with Medcan.
